Pharmaco Economics Analysis of COVID-19 Vaccines in Ukraine

Abstract

Aims: To evaluate pharmacoeconomics for the vaccination of COVID-19 vaccine and analyze the cost-effectiveness for the vaccine in Ukraine.
 Study design: we have analyzed using models for the economics of coronavirus vaccine.
 Place and duration of study: Sample: population of Ukraine, data used from the official website of Ministry of Health, Ukraine. April - May 2021
 Methodology: We have used the transmission model to analyze the vaccine strategy. Data were collected from official sources. We structured an age group model for evaluating high transmitters. Four strategies were organized and analyzed for analyzing the cost-effective strategy vaccination for everyone, no vaccination, and vaccination for old age only, high transmitters’ vaccination.
 Results: we have analyzed country specific cost-effective strategy for Ukraine depends upon the pandemic and economics of the country. Vaccinating older people was found to be the economically effective for Ukraine. In these study influences of discount rate analysis on QALY in Ukraine was done. When we vaccinate, high transmitters’ ratio was found to be 8.8% higher than for the elderly. This analysis suggests that vaccinating first the elderly group would not be so cost-effective. While doubling the cost for the vaccine, if the vaccine is available early with the scenario of pre-existing immunity has shifted cost-effectiveness for high transmitters than for the elderly in Ukraine
 Conclusion: we conclude from our pharmacoeconomic research study that cost effective analysis depends on pandemic and vaccinating elderly would be effective economically.

Effectiveness and Cost-Effectiveness of Inactivated Vaccine to Address COVID-19 Pandemic in China: Evidence From Randomized Control Trials and Real-World Studies

“…As for low- and middle-income countries, vaccination was cost-saving from a societal perspective ( 10 , 48 ). A Ukraine study illustrated that the priority strategy for older adults was more cost-effective when vaccine supply was insufficient ( 49 ). However, the majority of these studies used a vaccine with hypothetical efficacy, coverage rate, and cost data, and none of the studies mentioned the type of vaccine.…”

Cost‐effectiveness of COVID‐19 vaccination: A systematic review

“…Of the 28 included studies, 13 were from highincome countries (HICs): America (n = 7), [9][10][11][12][13][14][15] Italy (n = 2), 16,17 Canada (n = 1), 18 Denmark (n = 1), 19 the United Kingdom (n = 1), 20 and Spain (n = 1). 21 The remaining studies were from less developed countries, specifically, China (n = 3), [22][23][24] Brazil (n = 2), 25,26 Turkey (n = 1), 27 Iran (n = 1), 28 Pakistan (n = 1), 29 Colombia (n = 1), 30 South Africa (n = 1), 31 Thailand (n = 1), 32 Ukraine (n = 1), 33 Poland (n = 1), 34 Kenya (n = 1), 35 and multiple countries/regions (n = 1). 36 For the publication years, 15 studies were published in 2021, [11][12][13][14][15][16][18][19][20]22,27,29,[31][32][33] and 13 were published in the first half of 2022.…”

“…21 The remaining studies were from less developed countries, specifically, China (n = 3), [22][23][24] Brazil (n = 2), 25,26 Turkey (n = 1), 27 Iran (n = 1), 28 Pakistan (n = 1), 29 Colombia (n = 1), 30 South Africa (n = 1), 31 Thailand (n = 1), 32 Ukraine (n = 1), 33 Poland (n = 1), 34 Kenya (n = 1), 35 and multiple countries/regions (n = 1). 36 For the publication years, 15 studies were published in 2021, [11][12][13][14][15][16][18][19][20]22,27,29,[31][32][33] and 13 were published in the first half of 2022. 9,10,17,21,[23][24][25][26]28,30,[34][35][36] Regarding the study perspective, 12 studies were from the health system perspective, 10,12,[16]…”

“…36 For the publication years, 15 studies were published in 2021, [11][12][13][14][15][16][18][19][20]22,27,29,[31][32][33] and 13 were published in the first half of 2022. 9,10,17,21,[23][24][25][26]28,30,[34][35][36] Regarding the study perspective, 12 studies were from the health system perspective, 10,12,[16][17][18][19]23,25,26,30,31,33 10 were from the societal or payer perspective, 9,13,15,16,20,24,28,[34][35][36] ...…”

A Cost–Benefit Analysis of COVID-19 Vaccination in Catalonia

“…Some economic evaluations have estimated the cost-effectiveness of vaccination, with very favourable results [3][4][5][6][7], suggesting that vaccines against COVID can reduce healthcare costs by up to 60% [8]. Most of these approaches were conducted ex ante and/or using probabilistic models and highlight that the cost-effectiveness of the vaccination strategy depends on the extent of the infection and the vaccinated population exceeding a certain minimum threshold [9,10]. The consensus, then, is that the vaccination strategy against COVID is cost-effective, evidence that is in line with the economic evaluation of other vaccines, which, in Spain, show net savings or favourable cost-effective ratios [11].…”